Target intelligence / Profile preview

Peptidoglycan precursors containing D-alanyl-D-alanine (D-Ala-D-Ala)

Target
D-Ala-D-Ala
Molecular classification
Bacterial cell wall precursor, Peptidoglycan component, Glycolipid
01

Overview

Peptidoglycan precursors containing the D-alanyl-D-alanine (D-Ala-D-Ala) dipeptide are essential building blocks in the assembly of the bacterial cell wall, particularly in Gram-positive bacteria (Nature Reviews Microbiology, 2008). These precursors, including the membrane-anchored Lipid II, are synthesized in the cytoplasm and translocated to the outer surface of the cytoplasmic membrane. The D-Ala-D-Ala terminus acts as a critical recognition site for penicillin-binding proteins (PBPs), which facilitate the cross-linking of glycan strands to provide mechanical strength to the cell wall (PubMed, 2019). Glycopeptide antibiotics, such as vancomycin and teicoplanin, target this specific molecular motif by forming a complex via five hydrogen bonds (StatPearls, 2023). This interaction sterically blocks the enzymes responsible for peptidoglycan polymerization and cross-linking, leading to cell wall instability and osmotic lysis. Clinical resistance often arises through the metabolic reprogramming of these precursors to D-alanyl-D-lactate or D-alanyl-D-serine, which prevents antibiotic binding while maintaining cell wall function (Journal of Biological Chemistry, 2014).

Other names
D-alanyl-D-alanine terminusLipid IIUDP-N-acetylmuramyl-pentapeptidePeptidoglycan pentapeptide side chainD-Ala-D-Ala motif
02

Mechanism of action

Binding to the D-alanyl-D-alanine C-terminus of peptidoglycan precursors to sterically inhibit transglycosylation and transpeptidation during cell wall synthesis (StatPearls, 2023).

03

Biological functions

Cell wall biosynthesisPeptidoglycan cross-linkingBacterial cell wall assemblyStructural integrity maintenance
04

Disease associations

Bacterial infection
05

Safety considerations

NephrotoxicityOtotoxicityRed man syndrome (infusion reaction)Development of vancomycin-resistant enterococci (VRE)Vancomycin-resistant Staphylococcus aureus (VRSA)
06

Interacting drugs

Vancomycin

5 more in the full profile.

07

Biomarkers

vanA genevanB geneMinimum Inhibitory Concentration (MIC)Serum creatinine (for toxicity monitoring)

Beyond the preview

Go deeper on Peptidoglycan precursors containing D-alanyl-D-alanine (D-Ala-D-Ala).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Peptidoglycan precursors containing D-alanyl-D-alanine (D-Ala-D-Ala).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call